10x Genomics, Inc.
NASDAQ•TXG
CEO: Dr. Serge Saxonov Ph.D.
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2019-09-12
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Contact Information
Market Cap
$2.96B
P/E (TTM)
-67.5
53.8
Dividend Yield
--
52W High
$23.56
52W Low
$6.78
52W Range
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025
Financial Dashboard
Q4 2025 Data
Revenue
$166.03M+0.00%
4-Quarter Trend
EPS
-$0.13+0.00%
4-Quarter Trend
FCF
$39.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Driven by Settlements Revenue $642.8M, up 5.0%, driven by $44.1M non-recurring license and royalty income from settlements.
Net Loss Significantly Reduced Net loss narrowed sharply to $43.5M in 2025, a significant improvement from $182.6M loss reported in 2024.
Consumables Revenue Increased Consumables revenue increased 3.0% to $507.2M, led by Spatial consumables sales growing 19.0% year-over-year.
Strong Operating Cash Flow Operating cash flow provided $136.1M in 2025, reversing the prior year's $6.7M inflow, signaling better working capital management.
Risk Factors
Continued Operating Losses Risk Accumulated deficit reached $1.5B; company expects operating losses to continue in the near term despite recent gains.
Instrument Sales Decline Instrument revenue fell 39% to $56.8M due to lower volume and expected price decreases across product lines.
Government Funding Dependency Business heavily dependent on U.S. academic and government funding, creating vulnerability to budget cuts and delays.
Intellectual Property Litigation Exposure Ongoing intellectual property litigation against Parse, Curio, and Illumina poses financial and operational risks.
Outlook
Moderate 2026 Revenue Growth Expect revenues to moderately increase in 2026, excluding the significant non-recurring patent litigation settlement benefits.
Expense Management Focus Management plans R&D expense reduction of 10% and SG&A reduction of 8.2% for 2026 to manage spend.
Scale Bio Acquisition Integration Integrating Scale Bio acquisition completed in 2025; potential future contingent consideration payments up to $30.0M remain.
Capital Expenditure Planning Anticipating aggregate capital expenditures between $15M and $20M over next 12 months to support manufacturing and R&D.
Peer Comparison
Revenue (TTM)
$2.53B
$1.92B
$1.39B
Gross Margin (Latest Quarter)
350.9%
101.2%
99.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TXG | $2.96B | -67.5 | -5.7% | 15.1% |
| ESTA | $2.21B | -44.1 | -201.8% | 0.8% |
| GRDN | $2.13B | 52.0 | 24.7% | 8.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.3%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data